Wells Fargo analyst Yanan Zhu maintained a Buy rating on Beam Therapeutics yesterday and set a price target of $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yanan Zhu’s rating is based on several positive developments in Beam Therapeutics’ pipeline and financial performance. The company has made significant progress in its BEAM-302 AATD program, with additional patients dosed and promising dose responsiveness observed, alongside a strong safety profile. This progress, along with the introduction of a new dosing cohort, is expected to generate excitement ahead of the program update in early 2026.
Additionally, Beam Therapeutics reported better-than-expected earnings results for the second quarter of 2025, with a net loss per share that was narrower than consensus estimates. The company’s robust cash position of $1.2 billion is projected to support operations through 2028, allowing it to reach key milestones for several programs, including BEAM-101 and ESCAPE. These factors, combined with ongoing interactions with the FDA and upcoming data readouts, underpin Yanan Zhu’s Buy rating for the stock.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $43.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.